News
The DXd ADC portfolio currently consists of ENHERTU ®, a HER2 directed ADC, and DATROWAY ®, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback